Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Aram F. Hezel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-1690-8251; OpenAlex author ID A5007574547. Sources: ClinicalTrials.gov.

Their work

Papers
21 (first author 1, last author 1)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
105
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 1 paper · 2014: 1 paper · 2015: 2 papers · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: none · 2026: 1 paper, 1 trial

Papers 21

  1. UNC5B regulates epithelial-to-mesenchymal transition through a SRC-ZEB1 signaling axis to facilitate pancreatic cancer metastasis. Co-author DOI 10.1038/s41388-026-03908-4↗
  2. SWI/SNF chromatin remodeling complex in pancreatic ductal adenocarcinoma: Clinicopathologic and immunohistochemical study. Co-author DOI 10.1016/j.humpath.2024.01.013↗
  3. Netrin-1 feedforward mechanism promotes pancreatic cancer liver metastasis via hepatic stellate cell activation, retinoid, and ELF3 signaling. Co-author DOI 10.1016/j.celrep.2023.113369↗
  4. Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity. Co-author DOI 10.1158/0008-5472.can-22-3050↗
  5. Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-1125↗
  6. Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-3141↗
  7. Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.cell.2020.03.062↗
  8. Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-19-1315↗
  9. Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2019.1588↗
  10. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Co-author DOI 10.1038/s41436-018-0009-5↗
  11. Endocrine-exocrine signaling drives obesity-associated pancreatic ductal adenocarcinoma Co-author DOI 10.1101/663583↗
  12. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamaoncol.2017.3420↗
  13. Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. Co-author DOI 10.1038/bjc.2017.349↗
  14. Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s11605-016-3108-0↗
  15. Genetics and Biology of Pancreatic Ductal Adenocarcinoma. First author DOI 10.1016/j.hoc.2015.04.003↗
  16. Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-14-1591↗
  17. Plac8 links oncogenic mutations to regulation of autophagy and is critical to pancreatic cancer progression. Co-author DOI 10.1016/j.celrep.2014.03.061↗
  18. Unresectable locally advanced pancreatic cancer: treatment with neoadjuvant leucovorin, fluorouracil, irinotecan, and oxaliplatin and assessment of surgical re… Last author DOI 10.1200/jco.2012.44.0339↗
  19. A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer. Co-author DOI 10.1007/s10637-011-9708-3↗
  20. TGF-β and αvβ6 integrin act in a common pathway to suppress pancreatic cancer progression. Co-author DOI 10.1158/0008-5472.can-12-0634↗
  21. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. Co-author DOI 10.1158/2159-8290.cd-11-0031↗

Trials 1

  1. Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer Principal investigator NCT06203821↗

Closest collaborators

The 25 strongest of 105 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Richard Francis Dunne · 11 shared papers, 2015–2024 · strength 1.00
  2. Brian Matthew Wolpin · 10 shared papers, 2012–2023 · strength 0.72
  3. Albert C. Koong · 9 shared papers, 2017–2023 · strength 0.69
  4. Daniel Tandel Chang · 9 shared papers, 2017–2023 · strength 0.69
  5. Jonathan Andrew Nowak · 9 shared papers, 2017–2023 · strength 0.69
  6. Chen Yuan · 7 shared papers, 2017–2023 · strength 0.55
  7. Thomas E. Clancy · 7 shared papers, 2017–2023 · strength 0.55
  8. Douglas Adam Rubinson · 7 shared papers, 2017–2023 · strength 0.55
  9. Vicente Morales‐Oyarvide · 7 shared papers, 2017–2023 · strength 0.55
  10. Margaret M. Kozak · 7 shared papers, 2017–2023 · strength 0.55
  11. Andressa Dias Costa · 6 shared papers, 2019–2023 · strength 0.53
  12. Andrew J. Aguirre · 6 shared papers, 2018–2023 · strength 0.50
  13. Charles S. Fuchs · 7 shared papers, 2017–2021 · strength 0.47
  14. David C. Linehan · 6 shared papers, 2017–2023 · strength 0.47
  15. Sara A. Väyrynen · 5 shared papers, 2019–2023 · strength 0.45
  16. Darren R. Carpizo · 2 shared papers, 2023–2026 · strength 0.39
  17. Kimberly J. Perez · 4 shared papers, 2019–2023 · strength 0.36
  18. Ana Babić · 5 shared papers, 2017–2020 · strength 0.32
  19. Jiping Wang · 3 shared papers, 2021–2023 · strength 0.31
  20. Hannah L. Williams · 3 shared papers, 2021–2023 · strength 0.31
  21. Kimmie Ng · 5 shared papers, 2012–2022 · strength 0.31
  22. Diana Agostini‐Vulaj · 2 shared papers, 2021–2024 · strength 0.30
  23. Wenjia Wang · 2 shared papers, 2021–2024 · strength 0.30
  24. Muhammad Sadeqi Nezhad · 1 shared paper, 2026 · strength 0.25
  25. Stephano S. Mello · 1 shared paper, 2026 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.